Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

• Status: Completed
• Trial end date: 2008-06-11
• Target enrollment: 0
• Participant gender: All

Summary

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Glipizide; Metformin; Rosiglitazone; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patient has type 2 diabetes mellitus

• Patient is inadequately controlled while taking two oral antidiabetic medications

Exclusion Criteria:

• Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

• Patient required insulin therapy within the prior 3 months

• Patient has been taking Byetta (R) (exenatide) within the prior 3 months